Linagliptin treatment significantly enhanced tubular GLP-1R expression, with higher levels of GLP-1R staining evident in the proximal tubular area (Fig. 6B), which recovered to control levels even at 8 weeks after CKD onset. The gene discussed is GLP1R; the disease is chronic kidney disease.